We describe an unusual case of a woman in her 30s who had recently undergone Roux-en-Y gastric bypass and presented to the emergency department with a 6-week history of intractable nausea and vomiting ...

Reviva Pharmaceuticals Holdings Inc. may be headed back to the clinic for another phase III study of brilaroxazine in treating schizophrenia. The U.S. FDA recommended the second study for the ...

Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, ...

Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world’s first regulatory approval for pimicotinib, the first domestically ...

We have only just started to understand how our brains clean themselves, but columnist Helen Thomson finds promising evidence ...

Sacituzumab govitecan showed lower rates of dose reductions and treatment discontinuations due to adverse effects compared to chemotherapy in TNBC patients. Common adverse effects, such as diarrhea ...

It may contain inaccuracies due to the limitations of machine translation. Korea Science Journalists Association-Institute for Basic Science (IBS) Science Media Academy Director Gou Young-Gou of the ...

Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced the presentation of new CSF proteomic and ...

– After 14 days of treatment in healthy volunteers, ARV-102 decreased lysosomal and neuroinflammatory microglial pathway biomarkers known to be elevated in Parkinson’s disease – NEW HAVEN, Conn., Oct.

– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects ...

SAN FRANCISCO--(BUSINESS WIRE)-- Chime® (Nasdaq: CHYM), a leading consumer financial technology company, today announced its 2025–2026 Chime Scholars Foundation® (CSF) cohort, awarding over $3 million ...